PaineWebber analyst Linda Miller raised her rating on IcosCorp. to "neutral" from "unattractive" based on the price of theSeattle-based company's stock. Icos stock (NASDAQ:ICOS)closed unchanged Friday at $15.25.
Miller had lowered her rating to unattractive from neutral inmid-August based on the stock's 250 percent priceappreciation since July. Icos, which is developing drugs totreat chronic inflammatory diseases, completed an initialpublic offering in June at $8.
(c) 1997 American Health Consultants. All rights reserved.